You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信铭生命科技(00474.HK)就治疗痛楚药物许可签署谅解备忘录
格隆汇 03-24 18:59

格隆汇 3 月 24日丨信铭生命科技(00474.HK)发布公告,公司已与Scilex Holding(一间特拉华州公司)签署谅解备忘录,以就以下事项进行为期九十日的独家磋商:

(a)Scilex SP-102(SEMDEXA)(“SP-102”)在大中华地区的独家许可。SP-102是Scilex的专利药品,在美国处于关键三期试验,并获美国食品及药品监督管理局颁发快速审评资格;及(b)就公司向中国国家药品监督管理局申请在中国内地进口、制造及销售SEMDEXA或SP-102方面提供所须的临床前研究及临床测试数据。

谅解备忘录概述Scilex与公司之间就SP-102(一种新型非鸦片类注射式黏性药物,在大中华地区用于治疗痛症及坐骨神经痛)的产品开发、制造及商业化权利的专营权。根据内部评估,大中华地区的独家许可的预计总值将介乎6000万美元至8000万美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account